Using plasma proteomics to understand Alzheimer’s and other brain diseases
Using plasma proteomics to understand Alzheimer’s and other brain diseases
The plasma proteome presents a goldmine of information that can be used to develop diagnostic tests and identify novel drug targets. In this webinar, our expert speaker Dr. Keenan Walker describes his research into understanding the proteins, protein networks and biological pathways involved in age-related neurodegenerative diseases and vascular cognitive impairment.
Dr. Walker discusses how he integrates proteomic, genetic, brain imaging and cerebrospinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.
Learn about:
- Proteins most strongly implicated in dementia risk
- How combining proteomics with neuroimaging to provide new insights into cerebral small vessel disease
- The process of nominating potentially casual proteins and genetically validating biomarkers
Keenan Walker, PhD
Chief, Multimodal Imaging of Neurodegenerative Disease (MIND)
National Institute on Aging
Keenan Walker, PhD, is an investigator at the National Institute on Aging Intramural Research Program and Chief of the Multimodal Imaging of Neurodegenerative Disease (MIND) unit. Dr. Walker’s current research program focuses on understanding the role of abnormal immune function in Alzheimer’s disease and late-life cognitive decline.
Using plasma proteomics to understand Alzheimer’s and other brain diseases
A presentation by Keenan Walker, PhD
More webinars
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.
WebinarUsing Antibody Profiling to Identify Novel Diagnostic Biomarkers
Current cancer screening methods often lead to false positives, false negatives and invasive biopsies that lack prognostic insights. Emerging research suggests that cancer-specific IgM and IgG antibodies – produced by B cells upon recognizing malignant cells – could serve as stable, easily measurable blood biomarkers for detecting and monitoring high-incidence cancers like melanoma and breast, prostate, bowel, lung and pancreatic cancer. This approach has the potential to improve early diagnosis, reduce uncertainty and enhance treatment planning.
WebinarLinking the plasma proteome to echocardiographic parameters in patients with chronic heart failure
Recent advancements in proteomic profiling have unlocked new possibilities for understanding the complex mechanisms that drive heart failure. Measuring thousands of proteins simultaneously makes it possible to capture a comprehensive overview of the patient's health state and investigate underlying disease progression at a subclinical level.